The purpose of this article is to describe in detail how an academic hospital system took on the challenge of deep vein thrombosis (DVT) prevention. A VTE Prevention Task Force was formed in response to an increased incidence of hospital acquired DVTs. The interdisciplinary team reviewed the literature and examined the current state of organizational venous thromboembolism (VTE) prevention to identify gaps in process, determine opportunity and approaches for practice and process improvements, and develop standardized VTE prevention protocols. The article discusses the process taken in developing a highly motivated interdisciplinary team, the implementation of a care bundle, and the highly effective educational and surveillance tools used that helped improve patient outcomes by driving down the VTE rate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/NOR.0000000000000497 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Racial disparities in extended venous thromboembolism prophylaxis after hysterectomy.
PLoS One
January 2025
Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, United States of America.
Background: Venous thromboembolism (VTE) is a significant preventable cause of postoperative morbidity and mortality after major abdominopelvic surgery that calls for extended VTE prophylaxis (eVTEp). Literature suggests that significant racial disparities may exist in post-operative care.
Objective: The study sought to examine if racial disparities exist in the administration of eVTEp after hysterectomy in a statewide collaborative.
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair.
Cochrane Database Syst Rev
January 2025
Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Indiana University School of Medicine, Indianapolis, USA.
Background: People undergoing major orthopaedic surgery are at increased risk of postoperative thromboembolic events. Low molecular weight heparins (LMWHs) are recommended for thromboprophylaxis in this population. New oral anticoagulants, including direct factor Xa inhibitors, are recommended as alternatives.
View Article and Find Full Text PDFPrevention and Treatment of Venous Thromboembolism Associated with Amivantamab-Based Therapies in Patients with Lung Cancer-Provisional Clinical Opinion Based on Existing Clinical Practice Guidelines.
Cancers (Basel)
January 2025
Department of Medicine I, Division of Haematology & Haemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Improved efficacy has been shown for amivantamab and amivantamab-based combination therapies in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) compared to established treatment options in clinical trials. However, a high risk of venous thromboembolism (VTE) was observed in patients treated with amivantamab-based therapies, with considerable differences in VTE risk according to the line of systemic treatment, concomitant treatment with lazertinib, and intravenous vs. subcutaneous amivantamab administration.
View Article and Find Full Text PDFThe Link Between Venous and Arterial Thrombosis: Is There a Role for Endothelial Dysfunction?
Cells
January 2025
Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20125 Milan, Italy.
Venous thromboembolism (VTE) and arterial thrombosis (AT) are distinct yet closely related pathological processes. While traditionally considered separate entities, accumulating evidence suggests that they share common risk factors, such as inflammation and endothelial dysfunction (ED). This review explores the parallels and differences between venous and arterial thrombosis, with particular attention to the role of unprovoked VTE and its potential links to atherosclerosis and systemic inflammation.
View Article and Find Full Text PDFVenous thromboembolism (VTE) prevention program implementation in a community oncology practice: author response to Yang et al.
Lancet Reg Health Am
February 2025
University of Vermont Cancer Center, 89 Beaumont Ave, Burlington, VT, 05405, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!